Transcend Capital Advisors LLC Acquires 304 Shares of Regeneron Pharmaceuticals,
December 30, 2022
Trending News ☀️
Regeneron Pharmaceuticals ($NASDAQ:REGN), Inc. is a biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions such as cancer, inflammation, cardiovascular and metabolic diseases. Headquartered in Tarrytown, New York, Regeneron has operations in the United States, Canada, and other countries. Its products include EYLEA, Dupixent, Praluent, Kevzara, Libtayo, and Sarilumab. This purchase is part of a larger trend of institutional investors acquiring shares of Regeneron Pharmaceuticals, Inc. since the beginning of 2021.
Price History
On Tuesday, the company’s stock opened at $726.4 and closed at $711.4, representing a dip of 2.1% from the previous day’s closing price of $726.7. Transcend Capital Advisors LLC is a financial services company based in New York City. The company provides financial advice and investment services to individuals and institutions. The company has been actively investing in the stock market and making strategic purchases of shares in various companies. The company’s strategy of buying shares in companies that have a potential for growth has paid off in the past and is likely to continue to do so in the future.
The company develops, manufactures, and markets drugs to treat serious medical conditions, such as cancer, cardiovascular diseases, and autoimmune disorders. Given its strong track record in the healthcare industry and its cutting-edge drug development strategies, Regeneron Pharmaceuticals Inc. is an attractive target for investment for Transcend Capital Advisors LLC. The company’s latest acquisition of 304 shares of Regeneron Pharmaceuticals Inc. could be a move to capitalize on the company’s growth potential in the future. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Regeneron Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 13.71k | 5.37k | 40.6% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Regeneron Pharmaceuticals. More…
| Operations | Investing | Financing |
| 5.67k | -3.94k | -1.67k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Regeneron Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 27.68k | 6.24k | 197.05 |
Key Ratios Snapshot
Some of the financial key ratios for Regeneron Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 21.6% | 42.1% | 44.4% |
| FCF Margin | ROE | ROA |
| 30.3% | 18.1% | 13.8% |
VI Analysis
REGENERON PHARMACEUTICALS, a pharmaceutical company, has its fundamentals reflecting its long term potential. However, according to the risk rating given by the VI App, the company is rated as a high-risk investment in terms of financial and business aspects. The VI App has detected three risk warnings from the company’s balance sheet, cashflow statement and financial journal. The balance sheet gives an overview of the company’s financials such as assets, liabilities and shareholder equity, which help in determining the financial strength of the company. The cashflow statement provides information on how much money is coming in and going out of the business. The financial journal gives insight into the performance of the company over a period of time. These risk warnings need to be considered before investing in REGENERON PHARMACEUTICALS. By becoming a registered user of the VI App, investors can find out more about the risk warnings and understand their implications on the company. This can help them make informed decisions while investing in the company. More…
VI Peers
The company’s competitors include Cue Biopharma Inc, CytoDyn Inc, and Belite Bio Inc.
– Cue Biopharma Inc ($NASDAQ:CUE)
The company’s market cap is $94.12M and its ROE is -48.38%. Cue Biopharma is a clinical-stage biopharmaceutical company that uses its proprietary technology to develop immuno-oncology and immuno-inflammation therapeutics. The company’s immuno-oncology product candidates are designed to target cancer cells and tumor-associated antigens. The company’s immuno-inflammation product candidates are designed to target pro-inflammatory cytokines.
– CytoDyn Inc ($OTCPK:CYDY)
CytoDyn Inc is a clinical stage biotechnology company. The company is focused on the development and commercialization of novel therapies for treating autoimmune diseases, cancer, and human immunodeficiency virus. CytoDyn’s lead product candidate is leronlimab, a monoclonal antibody that inhibits the CCR5 receptor.
Summary
Regeneron Pharmaceuticals, Inc. has seen positive investor sentiment with Transcend Capital Advisors LLC acquiring 304 shares in the company. Analysts suggest that the company’s pipeline of potential drugs and therapies and strong financial results have driven share prices to new highs. Regeneron is currently focusing on treatments and potential cures for a range of diseases, including cancer, macular degeneration, rheumatoid arthritis, and asthma.
The company has also invested heavily in research and development to further its innovative capabilities and bring groundbreaking treatments to market. With its diverse portfolio and promising future, Regeneron Pharmaceuticals is an attractive option for investors looking for long-term growth in the healthcare sector.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
